Neuralink's "Blindsight" device, developed by Elon Musk's company, aims to restore vision for blind individuals.

Elon Musk's brain-chip startup Neuralink announces its experimental implant can restore vision, receives US FDA 'breakthrough device' designation.

The FDA approval given to Musk's start-up Neuralink allows for human testing. A look at how Blindsight works & Neuralink’s controversial work over the years.

Elon Musk's brain-chip startup Neuralink said on Tuesday its experimental implant aimed at restoring vision received the U.S. Food and Drug Administration's "breakthrough device" designation.

In his tweet, Elon Musk also said that the experimental device would "even enable those who have been blind from birth to see for the first time" provided that the visual cortex is intact.

Blindsight, the experimental vision-restoring implant by Elon Musk’s brain-chip startup, Neuralink, has received the U.S. Food and Drug Administration’s (FDA) "breakthrough device" designation, according to the company.

Neuralink confirmed the FDA approval and stated that Blindsight has been awarded the Breakthrough Device Designation.

Nonetheless, although the news has sparked much enthusiasm, what Blindsight is capable of—particularly in terms of regaining sight to its optimal capacity—is not as easy as Musk’s declarations imply.